Rahul D. Ballal - Net Worth and Insider Trading

Rahul D. Ballal Net Worth

The estimated net worth of Rahul D. Ballal is at least $1 Million dollars as of 2024-11-05. Rahul D. Ballal is the CEO of Imara Inc and owns about 120,696 shares of Imara Inc (IMRA) stock worth over $762,799. Rahul D. Ballal is also the Director of Enliven Therapeutics Inc and owns about 22,341 shares of Enliven Therapeutics Inc (ELVN) stock worth over $618,846. Details can be seen in Rahul D. Ballal's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Rahul D. Ballal has not made any transactions after 2024-10-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Rahul D. Ballal

Rahul D. Ballal Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Rahul D. Ballal owns 3 companies in total, including Imara Inc (IMRA) , Agios Pharmaceuticals Inc (AGIO) , and Enliven Therapeutics Inc (ELVN) .

Click here to see the complete history of Rahul D. Ballal’s form 4 insider trades.

Insider Ownership Summary of Rahul D. Ballal

Ticker	Comapny	Transaction Date	Type of Owner
IMRA	Imara Inc	2023-01-30	director & President & CEO
AGIO	Agios Pharmaceuticals Inc	2022-08-11	director
ELVN	Enliven Therapeutics Inc	2024-10-08	director & President & CEO

Rahul D. Ballal Latest Holdings Summary

Rahul D. Ballal currently owns a total of 2 stocks. Among these stocks, Rahul D. Ballal owns 120,696 shares of Imara Inc (IMRA) as of January 30, 2023, with a value of $762,799 and a weighting of 55.21%. Rahul D. Ballal also owns 22,341 shares of Enliven Therapeutics Inc (ELVN) as of October 8, 2024, with a value of $618,846 and a weighting of 44.79%.

Latest Holdings of Rahul D. Ballal

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
IMRA	Imara Inc	2023-01-30	120,696	6.32	762,799
ELVN	Enliven Therapeutics Inc	2024-10-08	22,341	27.70	618,846

Holding Weightings of Rahul D. Ballal

Rahul D. Ballal Form 4 Trading Tracker

According to the SEC Form 4 filings, Rahul D. Ballal has made a total of 3 transactions in Imara Inc (IMRA) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Imara Inc is the sale of 11,313 shares on January 30, 2023, which brought Rahul D. Ballal around $44,234.

According to the SEC Form 4 filings, Rahul D. Ballal has made a total of 5 transactions in Enliven Therapeutics Inc (ELVN) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Enliven Therapeutics Inc is the sale of 10,420 shares on October 8, 2024, which brought Rahul D. Ballal around $293,531.

Insider Trading History of Rahul D. Ballal

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Rahul D. Ballal Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Rahul D. Ballal Ownership Network

Ownership Network List of Rahul D. Ballal

No Data

Ownership Network Relation of Rahul D. Ballal

Rahul D. Ballal Owned Company Details

What does Imara Inc do?

Who are the key executives at Imara Inc?

Rahul D. Ballal is the director & President & CEO of Imara Inc. Other key executives at Imara Inc include See Remarks Michael Gray , 10 percent owner Braden Michael Leonard , and 10 percent owner Ra Capital Healthcare Fund Lp .

Imara Inc (IMRA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Imara Inc (IMRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Imara Inc (IMRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Imara Inc (IMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Imara Inc Insider Transactions

No Available Data

What does Agios Pharmaceuticals Inc do?

Who are the key executives at Agios Pharmaceuticals Inc?

Rahul D. Ballal is the director of Agios Pharmaceuticals Inc. Other key executives at Agios Pharmaceuticals Inc include Chief Financial Officer Cecilia Jones , director & Chief Executive Officer Brian Goff , and Chief Medical Officer Sarah Gheuens .

Agios Pharmaceuticals Inc (AGIO) Insider Trades Summary

Over the past 18 months, Rahul D. Ballal made no insider transaction in Agios Pharmaceuticals Inc (AGIO). Other recent insider transactions involving Agios Pharmaceuticals Inc (AGIO) include a net sale of 9,416 shares made by Washburn Theodore James Jr. , a net sale of 64,534 shares made by Brian Goff , and a net sale of 14,160 shares made by James William Burns .

In summary, during the past 3 months, insiders sold 13,633 shares of Agios Pharmaceuticals Inc (AGIO) in total and bought 0 shares, with a net sale of 13,633 shares. During the past 18 months, 252,596 shares of Agios Pharmaceuticals Inc (AGIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 252,596 shares.

Agios Pharmaceuticals Inc (AGIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Agios Pharmaceuticals Inc Insider Transactions

No Available Data

What does Enliven Therapeutics Inc do?

Who are the key executives at Enliven Therapeutics Inc?

Rahul D. Ballal is the director & President & CEO of Enliven Therapeutics Inc. Other key executives at Enliven Therapeutics Inc include Chief Financial Officer Benjamin Hohl , director & President and CEO Samuel Kintz , and Chief Operating Officer Anish Patel .

Enliven Therapeutics Inc (ELVN) Insider Trades Summary

Over the past 18 months, Rahul D. Ballal made 5 insider transaction in Enliven Therapeutics Inc (ELVN) with a net sale of 97,420. Other recent insider transactions involving Enliven Therapeutics Inc (ELVN) include a net sale of 240,342 shares made by Samuel Kintz , a net sale of 239,847 shares made by Joseph P Lyssikatos , and a net sale of 88,314 shares made by Benjamin Hohl .

In summary, during the past 3 months, insiders sold 183,359 shares of Enliven Therapeutics Inc (ELVN) in total and bought 0 shares, with a net sale of 183,359 shares. During the past 18 months, 4,855,709 shares of Enliven Therapeutics Inc (ELVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,855,709 shares.

Enliven Therapeutics Inc (ELVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Enliven Therapeutics Inc Insider Transactions

No Available Data

Rahul D. Ballal Mailing Address

Above is the net worth, insider trading, and ownership report for Rahul D. Ballal. You might contact Rahul D. Ballal via mailing address: 116 Huntington Avenue, 6th Floor, Boston Ma 02116.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.